NIAGEN BIOSCIENCE, INC.

NAGE ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2017 FY2016 FY2015 FY2013 FY2012 FY2011
Revenue $21.2M $21.7M $15.3M $10.2M $11.6M $8.1M
Cost of Revenue $10.7M $11.3M $10.0M $7.0M $9.3M $5.6M
Gross Profit $10.5M $10.4M $5.3M $3.1M $2.3M $2.5M
Gross Margin 49.4% 48.0% 34.8% 30.8% 19.6% 30.5%
Operating Expenses
Research & Development $4.0M $2.5M $513.7K $134.0K $142.0K $96.8K
SG&A Expense $17.6M $9.2M $7.9M $5.0M $8.4M $7.8M
Operating Income $-16.4M $-2.9M $-5.2M $-4.4M $-11.6M $-7.9M
Operating Margin -77.2% -13.4% -34.2% -43.2% -100.2% -96.9%
Interest Expense $153.0K $333.3K $158.8K $34.3K $29.0K $-32.1K
Pretax Income $-16.5M $-3.6M $-5.4M $-4.4M
Income Tax Expense $0 $0 $0
Net Income $-11.4M $-2.9M $-5.4M $-4.4M $-11.7M $-7.9M
Net Margin -53.7% -13.5% -35.2% -43.5% -100.4% -97.3%
EPS (Basic) $-0.26 $-0.08 $-0.15 $-0.04 $-0.13 $-0.12
EPS (Diluted) $-0.26 $-0.08 $-0.15 $-0.04 $-0.13 $-0.12
Shares Outstanding (Basic) 54.7M 37.3M 35.5M 100.0M 90.3M 68.3M
Shares Outstanding (Diluted) 54.7M 37.3M 35.5M 100.6M 96.0M 76.0M
Dividends Per Share
← Newer Page 2 of 2 Older →